References
- Augsburger LL, Shangraw RF. (1966). Effect of glidants in tableting. J Pharm Sci 55:418–23
- Carr RL. (1965). Evaluating flow properties of solids. Chem Eng 18:163–8
- Dressman JB, Berardi RR, Dermentzoglou LC, et al. (1990). Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7:756–61
- Dressman J, Kramer J. (2005). Pharmaceutical dissolution testing. : Boca Raton, FL, USA. 213–19
- El-Hammadi M, Awad N. (2012). Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release. AAPS PharmSciTech 13:53–8
- Fordtran JS, Locklear TW. (1966). Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis 11:503–21
- Hausner H. (1967). Friction conditions in a mass of metal powder. Int J Powder Metall 3:7–13
- International Conference on Harmonisation (ICH). (2003). Stability testing of new drug substances and products Q1A(R2). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf
- Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. (2007a). Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm 341:26–34
- Javadzadeh Y, Siahi MR, Asnaashari S, Nokhodchi A. (2007b). An investigation of physicochemical properties of piroxicam liquisolid compacts. Pharm Dev Technol 12:337–43
- Kostewicz ES, Wunderlich M, Brauns U, et al. (2004). Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 56:43–51
- Kumagai Y, Fujita T, Ozaki M, et al. (2005). Pharmacokinetics ofmosapride citrate in patients withgastrectomy. Clin Pharmacol Ther 77:51–3
- Mizuta Y, Shikuwa S, Isomoto H, et al. (2006). Recent insights into digestive motility in functional dyspepsia. J Gastroenterol 41:1025–40
- Moser K, Kriwet K, Froehlich C, et al. (2001). Permeation enhancement of a highly lipophilic drug using supersaturated systems. J Pharm Sci 90:607–16
- Ramenskaia GV, Shokhin IE, Savchenko AI, Volkova EA. (2011). The dissolution test in biorelevant media as a prognostic tool for modeling of drug behavior in vivo. Biomed Khim 57:482–9
- Reppas C, Vertzoni M. (2012). Biorelevant in-vitro performance testing of orally administered dosage forms. J Pharm Pharmacol 64:919–30
- Ruth M, Hamelin B, Rohss K, Lundell L. (1998). The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 12:35–40
- Shangraw RF. (1989). Compressed tablets by direct compression. 2nd ed. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical dosage forms tablets. vol. 1. , Marcel Dekker Inc., 195–220
- Spireas S, Sadu S, Grover R. (1998). In vitro release evaluation of hydrocortisone liquisolid tablets. J Pharm Sci 87:867–72
- Spireas S, Wang T, Grover R. (1999). Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Dev Ind Pharm 25:163–8
- Spireas S, Sadu S. (1998). Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 166:177–88
- Staniforth JN. (2002). Powder flow. In: Aulton ME, ed. Pharmaceutics: the science of dosage form design. : Churchill Livingstone, 205–8
- Yoshikawa T, Yoshida N, Mine Y, Hosoki K. (1998). Affinity of mosapride citrate, a new gastroprokinetic agent, for 5-HT4 receptors in guinea pig ileum. Jpn J Pharmacol 77:53–9